1
|
Basin MF, Chadha P, Useva A, Ginzburg N, Ferry E. Investigation of intradetrusor onabotulinum toxin A efficacy and safety in older adults with urge urinary incontinence. Int Urol Nephrol 2024; 56:1559-1563. [PMID: 38071727 DOI: 10.1007/s11255-023-03891-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Accepted: 11/14/2023] [Indexed: 04/09/2024]
Abstract
PURPOSE Intradetrusor onabotulinum toxin A (BTX-A) has been demonstrated to be an effective treatment option for overactive bladder (OAB). However, concerns about frailty and frequent injections may deter its use in the elderly. This study aims to assess the safety, efficacy, and treatment duration of BTX-A in managing OAB in elderly women. METHODS We retrospectively reviewed female patients aged 70 and above who were diagnosed with OAB with predominant urge urinary incontinence and underwent intravesical BTX-A treatment. We collected demographic and clinical data, with repeat BTX-A injections re-administered upon patient-reported symptom recurrence. RESULTS Twenty-one female patients, median age 77 (range 71-92), were included. The median time between the first and second injection was 185 (84-448) days, 186 (105-959) days between the second and third injection, and increased to 206.5 (84-256) days between the third and fourth injection. However, the median interval trended downward after the fourth injection (Fig. 1). Patients with four or more injections had a shorter median interval between injections, 154 days, compared to those with fewer injections, 210 days. Two patients (6.9%) experienced urinary retention after the initial treatment, with 1 (2.2%) among a total of 46 subsequent treatments (Table 3). There were ten (13.3%) episodes of UTIs within 2 weeks of treatment. Patients reported improvement in symptoms following 93.3% of the injections. CONCLUSION This real-world study demonstrates that BTX-A effectively controls OAB symptoms in elderly women, with just two injections annually. BTX-A appears safe and efficacious for treating OAB in elderly females.
Collapse
Affiliation(s)
- Michael F Basin
- Department of Urology, SUNY Upstate University Hospital, Syracuse, NY, USA.
| | - Priyal Chadha
- Department of Urology, SUNY Upstate University Hospital, Syracuse, NY, USA
| | - Anastasija Useva
- Department of Urology, SUNY Upstate University Hospital, Syracuse, NY, USA
| | - Natasha Ginzburg
- Department of Urology, SUNY Upstate University Hospital, Syracuse, NY, USA
| | - Elizabeth Ferry
- Department of Urology, SUNY Upstate University Hospital, Syracuse, NY, USA
| |
Collapse
|
2
|
Randomized clinical trials assessing third-line therapies to treat non-neurogenic overactive bladder syndrome: a review about methodology. Int Urogynecol J 2021; 32:2603-2618. [PMID: 33770228 DOI: 10.1007/s00192-021-04688-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Accepted: 01/10/2021] [Indexed: 11/27/2022]
Abstract
INTRODUCTION AND HYPOTHESIS Using similar methodologies and outcome measures is crucial to allow pertinent literature reviews and meta-analyses. Therefore, this scoping review aims to compare methodologies of randomized clinical trials (RCTs) assessing the efficacy of third-line therapies to treat non-neurogenic OAB: intradetrusor onabotulinumtoxinA (BoNTA) injections, sacral neuromodulation (SNM) and posterior tibial nerve stimulation (PTNS). METHODS A literature search was conducted using the PubMed search database. Using filters, the search was limited to RCTs conducted on humans and written in English or French since 2000 which evaluated BoNTA injections, SNM and/or PTNS. RCTs focusing on pediatric or neurogenic OAB were excluded. For each included RCT, methodology was assessed using a standardized form investigating the study design, clinical outcomes and urodynamic outcomes. Inclusion criteria, sex ratio, blinding strategies, treatment arms, primary outcomes and delays for reevaluation were assessed. Availability of clinical and urodynamic outcomes was reported at baseline, 3 months and 6 months. RESULTS Thirty-one RCTs were included in the final synthesis. The most frequent main outcome measure was change in the number of urinary incontinence episodes in 35.5% and in the number of voids per day in 25.8%. Bladder diaries were lacking in 12.9%, 32.3% and 80.1% at baseline, 3 and 6 months, respectively, while 26% of studies reported the results of urodynamic studies at any point. CONCLUSION Heterogeneity in study designs and data collection was pointed out between RCTs assessing the efficacy of third-line therapies to treat non-neurogenic OAB. We therefore advocate for the development of specific research guidelines focusing on OAB-related therapies.
Collapse
|
3
|
Phé V, Gamé X. [Follow-up and evaluation of non-neurogenic OAB treatments]. Prog Urol 2020; 30:931-937. [PMID: 33220821 DOI: 10.1016/j.purol.2020.09.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Revised: 08/10/2020] [Accepted: 09/04/2020] [Indexed: 11/16/2022]
Abstract
INTRODUCTION The purpose of monitoring a patient treated for overactive bladder (OAB) is to ensure the effectiveness of the treatment and to detect any side effects. OBJECTIVE To synthesize current knowledge on the follow-up and the evaluation of non-neurogenic OAB treatments. METHOD A systematic literature review based on Pubmed, Embase, Google Scholar was conducted in June 2020. RESULTS The definition of success of OAB treatments is not consensual. Definitions of success in clinical trials usually use bladder diary data. However, they cannot always be transposed into clinical practice because they do not measure the overall effectiveness of a treatment, reported by the patient, or the satisfaction with the treatment. It is then necessary to have symptom questionnaires with an assessment of quality of life. Indeed, the concept of therapeutic success is different depending on the view of the physician or the patient. It is therefore important to carefully assess with the patient, and before initiating any treatment, the objectives and expected results of the treatment. The definition of "refractory" OAB is heterogeneous but important to select candidates for second-line treatments. Monitoring a patient with OAB is essential to adapt the treatment to efficacy and tolerance, but also to detect any change in symptoms that may reveal another urological disease. CONCLUSION The success or failure of OAB treatments depends on the interaction of many factors, including objective criteria measured by the clinician, and subjective criteria of perception of the treatment effectiveness by the patient.
Collapse
Affiliation(s)
- V Phé
- Service d'urologie, hôpital Pitié-Salpêtrière, AP-HP Sorbonne université, Paris, France.
| | - X Gamé
- Département d'urologie, transplantation rénale et andrologie, CHU Rangueil, université Paul-Sabatier, Toulouse, France
| |
Collapse
|
4
|
Bels J, de Vries P, de Beij J, Marcelissen T, van Koeveringe G, Rademakers K. Long-term Follow-up of Intravesical Onabotulinum Toxin-A Injections in Male Patients with Idiopathic Overactive Bladder: Comparing Surgery-naïve Patients and Patients After Prostate Surgery. Eur Urol Focus 2020; 7:1424-1429. [PMID: 32919951 DOI: 10.1016/j.euf.2020.08.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Revised: 08/06/2020] [Accepted: 08/30/2020] [Indexed: 10/23/2022]
Abstract
BACKGROUND Evidence regarding long-term results in male idiopathic overactive bladder (iOAB) patients is limited and rarely focuses on the effects of prior prostatic surgery. OBJECTIVE This study aims to identify the long-term treatment persistency and occurrence of adverse events of intravesical onabotulinum toxin-A (BoNT-A) injections in male iOAB patients after prostatic surgery (ie, transurethral resection of the prostate [TURP] or radical prostatectomy [RP]) compared with surgery-naïve patients. DESIGN, SETTING, AND PARTICIPANTS In this retrospective, single-centre study, data from 477 patients treated with intravesical BoNT-A injections were collected. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Outcome data of 120 male patients with iOAB, with collectively 207 BoNT-A injections, were analysed and presented in this study. RESULTS AND LIMITATIONS At the last point of follow-up, 35 patients (29.2%) were still on active treatment. Twenty patients (16.7%) required de novo clean intermittent self-catheterisation (CISC). Three groups were identified: 56 patients without prostate surgery, 40 patients with TURP, and 24 patients with RP prior to treatment. Discontinuation rates and patient-reported outcomes of BoNT-A treatment (none, insufficient, or satisfactory) were similar, but a significant difference was seen in de novo CISC (p=0.004): 28.6% in the group without prior surgery, 7.5% in the TURP subgroup, and 4.2% in the RP subgroup. Odds of de novo CISC was significantly higher for the group without prior surgery than for both the TURP subgroup (odds ratio [OR] 4.9; 95% confidence interval [CI]: 1.33-18.31; p=0.017) and the RP subgroup (OR 9.2; 95% CI: 1.14-73.96; p= 0.037). CONCLUSIONS The data of this retrospective, single-centre cohort suggest that BoNT-A treatment leads to lower CISC rates in male patients after prior desobstructive surgery than in surgery-naïve patients. PATIENT SUMMARY This study describes the results of onabotulinum toxin-A (BoNT-A) injections in the bladder of male patients with idiopathic overactive bladder after initial prostate surgery compared with surgery-naïve patients. The results showed that BoNT-A treatment leads to lower catheterisation rates in patients after prior prostate surgery than in men without prior prostate surgery.
Collapse
Affiliation(s)
- Julia Bels
- Maastricht Universitair Medisch Centrum+, Maastricht, The Netherlands.
| | - Peter de Vries
- Department of Urology, Zuyderland Medisch Centrum, Sittard/Heerlen, The Netherlands
| | - Jeltje de Beij
- Department of Urology, Zuyderland Medisch Centrum, Sittard/Heerlen, The Netherlands
| | - Tom Marcelissen
- Department of Urology, Maastricht Universitair Medisch Centrum+, Maastricht, The Netherlands
| | - Gommert van Koeveringe
- Department of Urology, Maastricht Universitair Medisch Centrum+, Maastricht, The Netherlands
| | - Kevin Rademakers
- Department of Urology, Zuyderland Medisch Centrum, Sittard/Heerlen, The Netherlands
| |
Collapse
|
5
|
Abrar M, Pindoria N, Malde S, Chancellor M, DeRidder D, Sahai A. Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review. Eur Urol Focus 2020; 7:1448-1467. [PMID: 32616412 DOI: 10.1016/j.euf.2020.06.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Revised: 06/02/2020] [Accepted: 06/22/2020] [Indexed: 10/24/2022]
Abstract
CONTEXT Botulinum toxin A (BTX-A) injections are effective in managing refractory overactive bladder (OAB). However, some patients exhibit a poor response and/or experience adverse events (AEs) such as voiding dysfunction necessitating clean intermittent self-catheterisation (CISC) and urinary tract infections (UTIs). OBJECTIVE To systematically evaluate whether poor response/AEs to BTX-A for idiopathic OAB are predictable. EVIDENCE ACQUISITION MEDLINE, EMBASE, and Google Scholar database were searched in March 2020. Studies reporting predictive factors for poor response or AEs were included. Two reviewers independently screened articles, searched references, and extracted data. Risk of bias (Quality in Prognosis Studies [QUIPS]) and quality of evidence (Grading of Recommendations Assessment, Development and Evaluation [GRADE]) tools were utilised. EVIDENCE SYNTHESIS Of 1579 articles, 17 met the inclusion criteria. These were cohort studies with predominantly level 3 evidence. Factors including male gender, frailty, comorbidity, increasing age, smoking, baseline leakage episodes, and various urodynamic parameters (bladder outlet obstruction index [BOOI], high pretreatment maximum detrusor pressure, and poor bladder compliance) were proposed as predictors of nonresponse. In predicting CISC use, male gender, comorbidity, increasing age, number of vaginal deliveries, hysterectomy, and urodynamic parameters (bladder capacity, postvoid residual volume, projected isovolumetric pressure value, bladder contractility index, and BOOI) were implicated. Female gender, males with their prostates in situ, and CISC were suggested to increase UTIs after BTX-A. CONCLUSIONS This review has identified factors that may predict poor response/AEs following bladder BTX-A and help in counselling of patients. Overall, the quality of individual studies included was poor, limiting the certainty of evidence reported. Larger-scale, better-designed trials with uniform definitions of poor response are required to confirm these preliminary findings. PATIENT SUMMARY This review assessed whether we could predict poor response or side effects to bladder botulinum toxin A injections in managing overactive bladder. Many different factors based on the patient, medical conditions, previous surgery, and pretreatment investigations were identified. However, the quality of included studies was generally poor, limiting their conclusions.
Collapse
Affiliation(s)
- Mohammad Abrar
- Department of Urology, Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, UK
| | - Nisha Pindoria
- Department of Urology, Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, UK
| | - Sachin Malde
- Department of Urology, Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, UK
| | - Michael Chancellor
- Department of Urology, Oakland University William Beaumont School of Medicine and Beaumont Health System, Detroit, MI, USA
| | - Dirk DeRidder
- Department of Development and Regeneration, Organ Systems, KU Leuven, Leuven, Belgium
| | - Arun Sahai
- Department of Urology, Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, UK.
| |
Collapse
|
6
|
Management of Overactive Bladder After Treatment of Bladder Outlet Obstruction. CURRENT BLADDER DYSFUNCTION REPORTS 2019. [DOI: 10.1007/s11884-019-00527-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
|
8
|
Tamburro FR, Castellan P, Neri F, Berardinelli F, Bada M, Sountoulides P, Giuliani N, Finazzi Agrò E, Schips L, Cindolo L. Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience. Urologia 2018; 85:163-168. [DOI: 10.1177/0391560318759258] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Objective: Onabotulinumtoxin-A has been approved for wet overactive bladder refractory to anticholinergics in randomised controlled trials; however, data from real-life practice are scarce. This study was designed to assess the efficacy of intravesical onabotulinumtoxin-A injections, focusing on health status, urinary symptoms and subjective satisfaction. Methods: Data from consecutive patients with overactive bladder-refractory to anticholinergics treated with onabotulinumtoxin-A were prospectively collected and analysed. Standard doses (100–150 U) were used, followed by repeat sessions when clinical benefits diminished. Efficacy and safety of repeat onabotulinumtoxin-A administrations were assessed at 12-week post-injection. Clinical parameters evaluated were: change in the magnitude and frequency of incontinence, urgency and nocturia episodes, change in the number of pads used and procedural complications. Quality of life was evaluated using the 36-Item Short-Form Health Survey, Overactive Bladder Screener and Treatment Benefit Scale questionnaires. Results: Consecutive overactive bladder-refractory to anticholinergics patients ( n = 22) (median duration of oral therapy: 10 months) were enrolled. No intraoperative complications occurred, but two urinary retention cases were recorded. Forty-five percent of patients (10/22) were re-treated (median duration of perceived benefits: 18 months, range: 8–55 months). The number of urinary incontinence, frequency and nocturia episodes, and pads used went from 3.6, 11.3, 2.7 and 2.4 preoperatively to 1.0, 5.8, 0.7 and 0.7 postoperatively ( p < 0.005). Quality of life (36-Item Short-Form Health Survey) was significantly improved and symptom scores (Overactive Bladder Screener) were reduced, from 34.5 to 17.1 at week 12 ( p < 0.05). Eighty-seven percent of patients indicated improvement/great improvement in their condition (Treatment Benefit Scale). Conclusion: Intradetrusor injections of onabotulinumtoxin-A in patients with overactive bladder-refractory to anticholinergics significantly improved health status and urinary symptoms, with high subjective satisfaction.
Collapse
Affiliation(s)
- Fabiola R Tamburro
- Department of Urology, ASL02 Abruzzo, ‘S.Pio da Pietrelcina’ Hospital, Vasto, Italy
| | - Pietro Castellan
- Department of Urology, ASL02 Abruzzo, ‘S.Pio da Pietrelcina’ Hospital, Vasto, Italy
| | - Fabio Neri
- Department of Urology, ASL02 Abruzzo, ‘S.Pio da Pietrelcina’ Hospital, Vasto, Italy
| | | | - Maida Bada
- Department of Urology, ASL02 Abruzzo, ‘S.Pio da Pietrelcina’ Hospital, Vasto, Italy
- Department of Urology, G. d’Annunzio University of Chieti-Pescara, Chieti, Italy
| | | | - Nicola Giuliani
- Department of Urology, ASL02 Abruzzo, ‘S.Pio da Pietrelcina’ Hospital, Vasto, Italy
| | | | - Luigi Schips
- Department of Urology, ASL02 Abruzzo, ‘S.Pio da Pietrelcina’ Hospital, Vasto, Italy
- Department of Urology, G. d’Annunzio University of Chieti-Pescara, Chieti, Italy
| | - Luca Cindolo
- Department of Urology, ASL02 Abruzzo, ‘S.Pio da Pietrelcina’ Hospital, Vasto, Italy
| |
Collapse
|
9
|
Apostolidis A, Averbeck MA, Sahai A, Rahnama'i MS, Anding R, Robinson D, Gravas S, Dmochowski R. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015). Neurourol Urodyn 2017; 36:882-893. [DOI: 10.1002/nau.23170] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Accepted: 09/29/2016] [Indexed: 11/07/2022]
Affiliation(s)
- Apostolos Apostolidis
- 2nd Department of Urology; Aristotle University of Thessaloniki; Thessaloniki Greece
| | | | - Arun Sahai
- Department of Urology; Guy's and St.Thomas’ Hospitals; London UK
| | | | - Ralf Anding
- Department of Neurourology; University Hospital Bonn; Bonn Germany
| | - Dudley Robinson
- Department of Urogynaecology; King's College Hospital; NHS Foundation Trust; London UK
| | - Stavros Gravas
- Department of Urology; University of Thessaly; Larissa Greece
| | - Roger Dmochowski
- Department of Urology; Vanderbilt University; Nashville Tennesse
| |
Collapse
|
10
|
Moyson J, Legrand F, Vanden Bossche M, Quackels T, Roumeguère T. [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature]. Prog Urol 2017; 27:203-228. [PMID: 28228331 DOI: 10.1016/j.purol.2016.12.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Revised: 12/26/2016] [Accepted: 12/29/2016] [Indexed: 01/16/2023]
Abstract
OBJECTIVE Study the efficacy and adverse events of different pharmacological lines in the treatment of idiopathic overactive bladder (iOAB). METHODS PubMed research on meta-analyses and randomized controlled trials (RCT) focused on the efficacy and adverse effects of anticholinergics, botulinum toxin and mirabegron since 2005. RESULTS Ten meta-analyses of anticholinergics were selected; 16 randomized controlled trials (ERC) comparing botulinum toxin A to either anticholinergic or placebo and 10 ERC studying mirabegron. All the molecules studied showed efficacy compared to placebo in the treatment of iOAB. Anticholinergics remain the first-line pharmacological treatment allowing a significant reduction in the number (nb) of incontinence (-5/week) and in the number of urination (-4/week) as well as a perception of subjective improvement of the symptoms reported by 56 % of the patients treated against 41 % for the placebo group (RR: 1.39 [95 % CI: 1.28-1.51]). The most commonly reported side effect is dry mouth (30 % vs. 8 % in the placebo group). Injections of botulinum toxin A appear to be relatively comparable to anticholinergics in the first line with a decrease in urinary emergency incontinence (UTI) of 3.3/d in the toxin group versus 3.4/d in the anticholinergic group (P=0.81). There was also a higher rate of complete resolution of urinary incontinence in the toxin group (27 % vs. 13 % P=0.03) but significant adverse effects such as lower urinary tract infections (33 % vs. 13 % P>0.01). And the risk of using self-catheterization (5 % vs. 0 % P=0.01). In view of the invasive character of the toxin injections and their side effects, this treatment remains a 2nd line therapy. The same is true for mirabegron: similar efficacy (IUU number in the mirabegron group 50mg -1.74 vs. -1.53 In the solifenacin group 5mg, P>0.5) but different side effects with arterial hypertension (the oral dryness rate being comparable to that in the placebo group). The choice of use of anticholinergic or mirabegron should be based on the balance of efficacy/tolerance to be estimated for each patient. CONCLUSION The different molecules have shown their efficacy in the treatment of iOAB with acceptable tolerance. There is a lack of direct comparisons between treatments available. Further studies are needed to evaluate the possible interest of a combination of these molecules as well as the search for predictive factors of response to these different therapies.
Collapse
Affiliation(s)
- J Moyson
- Hôpital universitaire Erasme ULB, 808, route de Lennik, 1070 Bruxelles, Belgique.
| | - F Legrand
- Hôpital universitaire Erasme ULB, 808, route de Lennik, 1070 Bruxelles, Belgique
| | - M Vanden Bossche
- Hôpital universitaire Erasme ULB, 808, route de Lennik, 1070 Bruxelles, Belgique
| | - T Quackels
- Hôpital universitaire Erasme ULB, 808, route de Lennik, 1070 Bruxelles, Belgique
| | - T Roumeguère
- Hôpital universitaire Erasme ULB, 808, route de Lennik, 1070 Bruxelles, Belgique
| |
Collapse
|
11
|
Intermittent catheterisation after botulinum toxin injections: the time to reassess our practice. Int Urogynecol J 2017; 28:1351-1356. [PMID: 28116467 DOI: 10.1007/s00192-017-3271-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Accepted: 01/05/2017] [Indexed: 10/20/2022]
Abstract
INTRODUCTION AND HYPOTHESIS Botulinum toxin has become a widely adopted treatment for patients with recalcitrant overactive bladder (OAB) symptoms. Some recommend clean intermittent self-catheterisation (CISC) if a postvoid residual (PVR) >200 ml posttreatment, but there is no evidence for this recommendation. The aim of this study was to identify whether abstinence from CISC as a routine strategy for patients with a PVR following intradetrusor botulinum toxin injections is associated with any measurable adversity. METHODS This was a cohort observation study. Patients with lower urinary tract symptoms (LUTS) attending a medical urology centre were observed before and after botulinum toxin treatment. Intradetrusal botulinum toxin injections were administered in the day-treatment centre at a medical urology centre in London, UK. Patients were reviewed at follow-up consultations to measure PVR. RESULTS Of the 240 patients studied, 215 were women and 25 were men, of whom, 196 (82%) received botulinum toxin injections and were not managed with CISC; 18% were using CISC prior to injections and continued. None of the 196 patients developed acute retention or significant voiding symptoms. CONCLUSIONS Our study indicates that routine administration of CISC based on an arbitrary PVR volume is unlikely to confer benefit. In order to avoid patients being deterred from botulinum treatment, we recommend that CISC be reserved for those who have troublesome voiding symptoms as well as a raised PVR. It is unlikely that CISC, initiated on the basis of an arbitrary PVR volume, would benefit the patient.
Collapse
|
12
|
Perucchini D, Betschart C, Fink D, Scheiner DA. [Not Available]. PRAXIS 2017; 106:37-44. [PMID: 28055318 DOI: 10.1024/1661-8157/a002573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Zusammenfassung. OAB (overactive bladder syndrome) ist zwar ein häufiges Leiden, doch wird es oft nicht diagnostiziert und deshalb nicht behandelt. Die Behandlung erfolgt symptomatisch. Im Praxisalltag muss vorgängig eine Basis-(Ausschluss)-Diagnostik durchgeführt werden. Das Führen eines Blasentagebuchs ist sowohl für die Diagnostik als auch für den Verlauf wichtig. Eine urogynäkologische Abklärung mit Urodynamik empfiehlt sich in unklaren Situationen und beim Vorliegen einer gemischten Symptomatik mit Symptomen einer Belastungsinkontinenz oder bei gleichzeitigem Vorliegen einer Blasenentleerungsstörung. Die Therapie erfolgt Schritt für Schritt. Schon einfache Verhaltensänderungen und ein Blasen- und Beckenbodentraining können die Symptomatik deutlich verbessern. Viele Patientinnen profitieren aber zusätzlich von der medikamentösen Therapie. Jahrzehntelang standen dazu alleinig Anticholinergika zur Verfügung. Doch die Langzeitcompliance ist unter diesen Medikamenten gering. Neu erweitern β3-Adrenorezeptor-Agonisten das therapeutische Spektrum: Bei ähnlicher Wirkung unterscheidet sich das Nebenwirkungsprofil unter anderem durch das Fehlen von Mundtrockenheit. Bei therapierefraktärer OAB steht die intravesikale Injektion von Onabotulinumtoxin A als sehr effektive Therapie zur Verfügung. In seltenen Fällen ist auch eine Neuromodulation indiziert.
Collapse
Affiliation(s)
- Daniele Perucchini
- 1 Blasenzentrum Zürich Stadelhofen und Klinik für Gynäkologie, Universitätsspital Zürich
| | - Cornelia Betschart
- 1 Blasenzentrum Zürich Stadelhofen und Klinik für Gynäkologie, Universitätsspital Zürich
| | - Daniel Fink
- 1 Blasenzentrum Zürich Stadelhofen und Klinik für Gynäkologie, Universitätsspital Zürich
| | - David A Scheiner
- 1 Blasenzentrum Zürich Stadelhofen und Klinik für Gynäkologie, Universitätsspital Zürich
| |
Collapse
|
13
|
Olivera CK, Meriwether K, El-Nashar S, Grimes CL, Chen CCG, Orejuela F, Antosh D, Gleason J, Kim-Fine S, Wheeler T, McFadden B, Balk EM, Murphy M. Nonantimuscarinic treatment for overactive bladder: a systematic review. Am J Obstet Gynecol 2016; 215:34-57. [PMID: 26851599 DOI: 10.1016/j.ajog.2016.01.156] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2015] [Revised: 01/04/2016] [Accepted: 01/13/2016] [Indexed: 10/22/2022]
Abstract
The purpose of the study was to determine the efficacy and safety of nonantimuscarinic treatments for overactive bladder. Medline, Cochrane, and other databases (inception to April 2, 2014) were used. We included any study design in which there were 2 arms and an n > 100, if at least 1 of the arms was a nonantimuscarinic therapy or any comparative trial, regardless of number, if at least 2 arms were nonantimuscarinic therapies for overactive bladder. Eleven reviewers double-screened citations and extracted eligible studies for study: population, intervention, outcome, effects on outcome categories, and quality. The body of evidence for categories of interventions were summarized and assessed for strength. Ninety-nine comparative studies met inclusion criteria. Interventions effective to improve subjective overactive bladder symptoms include exercise with heat and steam generating sheets (1 study), diaphragmatic (1 study), deep abdominal (1 study), and pelvic floor muscle training exercises (2 studies). Pelvic floor exercises are more effective in subjective and objective outcomes with biofeedback or verbal feedback. Weight loss with diet and exercise, caffeine reduction, 25-50% reduction in fluid intake, and pelvic floor muscle exercises with verbal instruction and or biofeedback were all efficacious. Botulinum toxin A improves urge incontinence episodes, urgency, frequency, quality of life, nocturia, and urodynamic testing parameters. Acupuncture improves quality of life and urodynamic testing parameters. Extracorporeal magnetic stimulation improves urodynamic parameters. Mirabegron improves daily incontinence episodes, nocturia, number of daily voids, and urine volume per void, whereas solabegron improves daily incontinence episodes. Short-term posterior tibial nerve stimulation is more efficacious than pelvic floor muscle training exercises and behavioral therapy for improving: urgency, urinary incontinence episodes, daily voids, volume per void, and overall quality of life. Sacral neuromodulation is more efficacious than antimuscarinic treatment for subjective improvement of overactive bladder and quality of life. Transvaginal electrical stimulation demonstrates subjective improvement in overactive bladder symptoms and urodynamic parameters. Multiple therapies, including physical therapy, behavioral therapy, botulinum toxin A, acupuncture, magnetic stimulation, mirabegron, posterior tibial nerve stimulation, sacral neuromodulation, and transvaginal electrical stimulation, are efficacious in the treatment of overactive bladder.
Collapse
|
14
|
Broome JD, Irwin PP. Intravesical botulinum toxin-A: Does the injection template matter? JOURNAL OF CLINICAL UROLOGY 2016. [DOI: 10.1177/2051415816639781] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Objective: The efficacy of intravesical botulinum toxin-A (BTX-A) for the treatment of idiopathic detrusor overactivity (IDO) is well-established and evidence-based. The optimal regime in terms of dose, distribution, depth of injection and number of injections has not been determined and there is still considerable variation throughout clinical practice. We aim to establish the optimum template for bladder injections. Patients and methods: All patients had urodynamically-proven IDO which had failed conservative and medical management. AbobotulinumtoxinA (250 units) was injected into the detrusor and sub-urothelium in one of five injection templates under general anaesthetic. An Overactive Bladder Symptom Score (OABSS) and International Prostate Symptoms Score (IPSS)-Likert quality of life (QoL) score was completed pre-operatively and at six weeks post-operatively. In those who underwent repeat treatments the time to re-commencement of pharmacological therapy was recorded. Results: In total 111 patients received 170 treatments. The average age of patients was 57 (range: 17–86) and the male: female ratio was 0.18:1. Overall there was a mean improvement in the OABSS by −3.7 points±4.29 (standard deviation (SD) ( p<0.01) and an average change in the QoL score of −2.18±2.17 (SD) ( p<0.01) with BTX-A treatment. When analysed by template subgroup there was no statistically significant difference in the magnitude of change for any template over the other four for either the OABSS ( p=0.78) or QoL scores ( p=0.56). Forty-one patients had multiple treatments and had data collected for the duration to treatment failure. The overall average time to treatment failure was 11.2±7.9 months. Subgroup analysis showed that there was no statistically significant ( p=0.783) difference in time to treatment failure for any one of the injection distributions. Conclusion: This study has shown that altering the injection protocol of BTX-A did not affect the clinical outcome in terms of symptoms, QoL or in the time to treatment failure.
Collapse
Affiliation(s)
- JD Broome
- Michael Heal Urology Unit, Mid-Cheshire Hospitals NHS Foundation Trust, UK
| | - PP Irwin
- Michael Heal Department of Urology, Leighton Hospital, UK
| |
Collapse
|
15
|
Eight-Year Experience With Botulinum Toxin Type-A Injections for the Treatment of Nonneurogenic Overactive Bladder: Are Repeated Injections Worthwhile? Int Neurourol J 2016; 20:40-6. [PMID: 27032556 PMCID: PMC4819158 DOI: 10.5213/inj.1630450.225] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2015] [Accepted: 11/08/2015] [Indexed: 11/19/2022] Open
Abstract
Purpose: To investigate the efficacy and safety of repeated botulinum toxin type-A (BTX-A) injections for patients with drug-refractory nonneurogenic overactive bladder (NNOAB) and explore factors predictive of outcome. Methods: Data were collected from all patients receiving repeated BTX-A injections for drug-refractory NNOAB between 2004 and 2012. Trigone-sparing injections were administered under sedation with antibiotic prophylaxis. Patient characteristics including age, sex, preoperative urodynamics, injection number, BTX-A dose, complications, and patient global impression of improvement (PGI-I) scores were collected. Correlations between patient factors and outcomes were assessed by using Pearson’s chi-square tests. Results: Fifty-two patients with a mean age of 67.4 years (range, 26–93 years) received 140 BTX-A injections in total; 33 (64%), 15 (29%), and 4 patients (7%) received 2, 3 to 4, and 5 to 8 injections, respectively. Mean follow-up time was 49 months (range, 9–101 months). Nine patients developed urinary tract infection; additionally, 3 patients experienced transient urinary retention. Median PGI-I score was 2 out of 7 (interquartile range [IQR], 2). For 46 patients, the PGI-I score remained stable with the administration of each injection. Pearson chi-square tests revealed that male patients or reduced bladder compliance was associated with a higher (worse) PGI-I score. Median PGI-I scores for men and women were 3 (IQR, 1) and 2 (IQR, 1), respectively; additionally, median PGI-I scores for those with normal bladder compliance and those with reduced bladder compliance were 2 (IQR, 2) and 4.5 (IQR, 1), respectively. Median PGI-I scores and complication rates were the same in the older patient (≥70 years) and younger (<70 years) patient cohorts. Conclusions: Efficacy is maintained with repeated BTX-A injections. Patients including the elderly show a good degree of tolerability with a low complication rate. Male patients or reduced bladder compliance is associated with poorer outcomes.
Collapse
|
16
|
Patiño Sandoval GA, Sanchez Basto C, Iregui Parra JD, Fernández Bonilla JN. Guía vejiga hiperactiva no neurogénica en adultos. Guía de la Sociedad Colombiana de Urología. UROLOGÍA COLOMBIANA 2016. [DOI: 10.1016/j.uroco.2016.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
17
|
Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome. Int Neurourol J 2015; 19:213-9. [PMID: 26739175 PMCID: PMC4703928 DOI: 10.5213/inj.2015.19.4.213] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2015] [Accepted: 11/02/2015] [Indexed: 11/23/2022] Open
Abstract
Intravesical onabotulinumtoxinA (BoNT-A) injection is an effective treatment for overactive bladder syndrome (OAB) that is refractory to antimuscarinics. An injectable dose of 100 U has been suggested to achieve the optimal balance of benefit and safety in patients with OAB. BoNT-A (total volume of 10 mL) was administered as evenly distributed intradetrusor injections (5 U) across 20 sites approximately 1 cm apart (0.5 mL per site) using a flexible or rigid cystoscope. Treatment with BoNT-A was generally well tolerated by most patients, and most treatment-related adverse events were localized to the urinary tract. The prevalence of OAB increases with age, and elderly patients are more vulnerable to complications. The short-term efficacy of intravesical BoNT-A injection for refractory OAB with no treatment-related complications in the elderly population has been documented. Frail elderly patients can experience the same treatment results, such as significantly improved urgent urinary incontinence and quality of life, as young and nonfrail elderly patients with 100-U BoNT-A injections. However, increased risk of larger postvoid residual (PVR) urine and lower long-term success rates were noted in frail elderly patients; around 11% had acute urinary retention, while 60% had PVR urine volume >150 mL after treatment. In addition, intravesical injection of BoNT-A effectively decreased urgency symptoms in elderly patients with OAB and central nervous system lesions. The adverse effects were acceptable, while the long-term effects were comparable to those in patients with OAB without central nervous system lesions. Nonetheless, the possibility of longstanding urinary retention and chronic catheterization in this vulnerable population requires careful evaluation before treatment with intravesical BoNT-A. In conclusion, the current findings indicate that intravesical BoNT-A is an effective and safe treatment for OAB in elderly patients.
Collapse
|
18
|
Liao CH, Chen SF, Kuo HC. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study. Neurourol Urodyn 2015; 35:717-23. [DOI: 10.1002/nau.22780] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2015] [Accepted: 03/16/2015] [Indexed: 11/06/2022]
Affiliation(s)
- Chun-Hou Liao
- Division of Urology, Department of Surgery, Cardinal Tien Hospital, School of Medicine; Fu-Jen Catholic University; Taipei Taiwan
| | - Sheng-Fu Chen
- Department of Urology; Buddhist Tzu Chi General Hospital and Tzu Chi University; Hualien Taiwan
| | - Hann-Chorng Kuo
- Department of Urology; Buddhist Tzu Chi General Hospital and Tzu Chi University; Hualien Taiwan
| |
Collapse
|
19
|
Dasgupta P. Capsaicin, resiniferatoxin and botulinum toxin-A - a trip down memory lane. BJU Int 2015; 115:675. [DOI: 10.1111/bju.13138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Gamé X, Karsenty G, Ruffion A, Amarenco G, Ballanger P, Chartier-Kastler E, Cosson M, Costa P, Fatton B, Deffieux X, Haab F, Hermieu JF, Le Normand L, Saussine C, Denys P. [Idiopathic overactive bladder and BOTOX(®): Literature review]. Prog Urol 2015; 25:461-73. [PMID: 25662706 DOI: 10.1016/j.purol.2015.01.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2014] [Accepted: 01/12/2015] [Indexed: 11/29/2022]
Abstract
AIM Systematically review literature on the efficacy and tolerability of botulinum toxin A (onabotulinumtoxineA, BOTOX(®), Allergan, CA, USA) in refractory idiopathic overactive bladder (iOAB) METHODS: Pubmed search on the efficacy, toxicity and adverse events of onabotulinumtoxinA in clinical trials only with level 1 and 2 evidence. RESULTS Eleven controlled randomised trials have been selected, of which 3 phase III trials. The studies published data of 1008 patients with refractory iOAB treated with onabotulinumtoxineA. In the phase II and III trials, doses from 50 U to 300 U have been evaluated; more than half of the patients (n = 676) with 100 U. In the 2 main phase III trials, onabotulinumtoxinA has demonstrated to be more efficient compared to placebo on continence, symptoms and quality of live (QoL). Urodynamic results, reported in the phase II trials, demonstrated higher changes compared to placebo only from dose 100 U on, although not always significant. Adverse events (urinary retention, dysuria, urinary tract infection) were easily treated and did not influence patient's QoL. CONCLUSION Intradetrusor injections of onabotulinumtoxinA (BOTOX(®)), a minimally-invasive procedure, seem to be efficient and well tolerated in the treatment of refractory iOAB.
Collapse
Affiliation(s)
- X Gamé
- Service d'urologie, hôpital de Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France
| | - G Karsenty
- Service de chirurgie urologique et transplantation rénale, CHU de la Conception, Aix-Marseille université, 147, boulevard Baille, 13005 Marseille, France
| | - A Ruffion
- Service d'urologie, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France
| | - G Amarenco
- Service de rééducation neuro-urologique, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - P Ballanger
- Service d'urologie, hôpital Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - E Chartier-Kastler
- Service d'urologie, hôpital de la Pitié-Salpétrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - M Cosson
- Service de gynécologie, CHRU de Lille, rue Eugène-Avinée, 59037 Lille cedex, France
| | - P Costa
- Service d'urologie, CHRU Carémeau, rue du Professeur-Debré, 30029 Nîmes cedex 9, France
| | - B Fatton
- Service de gynécologie, CHRU Carémeau, rue du Professeur-Debré, 30029 Nîmes cedex 9, France
| | - X Deffieux
- Service de gynécologie-obstétrique, hôpital Antoine-Béclère, AP-HP, 157, rue de la Porte-Trivaux, 92140 Clamart, France
| | - F Haab
- Service d'urologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - J-F Hermieu
- Service d'urologie, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| | - L Le Normand
- Service d'urologie, Hôtel Dieu, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France
| | - C Saussine
- Service d'urologie, CHU, 1, place de l'Hôpital, 67000 Strasbourg, France
| | - P Denys
- Service de médecine physique et de réadaptation, hôpital Raymond-Poincaré, AP-HP, 104, boulevard Raymond-Poincaré, 92380 Garches, France.
| |
Collapse
|
21
|
Deffieux X, Fatton B, Denys P, Chartier-Kastler E, Amarenco G, Haab F, Costa P, Game X, Karsenty G, Saussine C, Ballanger P, Le Normand L, Ruffion A, Hermieu JF, Cosson M. [Intra-detrusor injection of botulinum toxin for female refractory idiopathic overactive bladder syndrome]. J Gynecol Obstet Hum Reprod 2014; 43:572-580. [PMID: 25087018 DOI: 10.1016/j.jgyn.2014.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2014] [Revised: 06/17/2014] [Accepted: 06/18/2014] [Indexed: 06/03/2023]
Abstract
INTRODUCTION Botulinum toxin-A detrusor injections are now approved for use (extension of marketing authorization) in the management of refractory idiopathic overactive bladder. The goal of the current study was to study the value and efficacy of this therapy. PATIENTS AND METHODS A literature review was performed on Medline, Embase and Cochrane databases, using the following keywords: botulinum toxin; overactive bladder syndrome; urinary incontinence; detrusor injection. RESULTS The recommended first step dose is 50 units of BOTOX(©) (dose selected for tolerance assessment). However, the cure rates for urge incontinence are greater with 100 units. Before proposing an injection, it is recommended to ensure the feasibility and acceptability of self-catheterisation by the patient, because of the risk of urinary retention (6%). The administration of BOTOX(©) comprises an intra-detrusor injection using a cystoscope, performed under local anesthesia. Clinical improvement is generally observed in the first two weeks after the injection. Patients should be considered for reinjection when the clinical effect of the previous injection has diminished, approximately 6-9 months after the first injection. An injection of 100 units may be considered when the clinical benefit of the 50-unit injection is not satisfactory concerning incontinence symptoms. CONCLUSION Botulinum toxin detrusor injections may be offered to women who develop refractory OAB.
Collapse
Affiliation(s)
- X Deffieux
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Antoine-Béclère, groupe hospitalier universitaire Sud, Assistance publique-Hôpitaux de Paris (AP-HP), 157, rue de La-Porte-de-Trivaux, 92414 Clamart, France.
| | - B Fatton
- Service de gynécologie, CHRU Carémeau, rue du Professeur-Debré, 30029 Nîmes cedex 9, France
| | - P Denys
- Service de médecine physique et de réadaptation, hôpital Raymond-Poincaré, 104, boulevard Raymond-Poincaré, 92380 Garches, France
| | - E Chartier-Kastler
- Service d'urologie, hôpital de la Pitié-Salpétrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - G Amarenco
- Service de rééducation neuro-urologique, hôpital Tenon, 4, rue de La-Chine, 75020 Paris, France
| | - F Haab
- Service d'urologie, hôpital Tenon, 4, rue de La-Chine, 75020 Paris, France
| | - P Costa
- Service d'urologie, CHRU Carémeau, rue du Professeur-Debré, 30029 Nîmes cedex 9, France
| | - X Game
- Service d'urologie, hôpital de Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France
| | - G Karsenty
- Service d'urologie, hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France
| | - C Saussine
- Service d'urologie, centre hospitalier universitaire, 1, place de l'Hôpital, 67000 Strasbourg, France
| | - P Ballanger
- Service d'urologie, hôpital Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - L Le Normand
- Service d'urologie, Hôtel-Dieu, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France
| | - A Ruffion
- Service d'urologie, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France
| | - J-F Hermieu
- Service d'urologie, hôpital Bichat, 46, rue Henri-Huchard, 75018 Paris, France
| | - M Cosson
- Service de gynécologie, CHRU de Lille, rue Eugène-Avinée, 59037 Lille cedex, France
| |
Collapse
|
22
|
Withington J, Hirji S, Sahai A. The changing face of urinary continence surgery in England: a perspective from the Hospital Episode Statistics database. BJU Int 2014; 114:268-77. [PMID: 24512557 DOI: 10.1111/bju.12650] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To quantify changes in surgical practice in the treatment of stress urinary incontinence (SUI), urge urinary incontinence (UUI) and post-prostatectomy stress incontinence (PPI) in England, using the Hospital Episode Statistics (HES) database. PATIENTS AND METHODS We used public domain information from the HES database, an administrative dataset recording all hospital admissions and procedures in England, to find evidence of change in the use of various surgical procedures for urinary incontinence from 2000 to 2012. RESULTS For the treatment of SUI, a general increase in the use of synthetic mid-urethral tapes, such as tension-free vaginal tape (TVTO) and transobturator tape (TOT), was observed, while there was a significant decrease in colposuspension procedures over the same period. The number of procedures to remove TVT and TOT has also increased in recent years. In the treatment of overactive bladder and UUI, there has been a significant increase in the use of botulinum toxin A and neuromodulation in recent years. This coincided with a steady decline in the recorded use of clam ileocystoplasty. A steady increase was observed in the insertion of artificial urinary sphincter (AUS) devices in men, related to PPI. CONCLUSIONS Mid-urethral synthetic tapes now represent the mainstream treatment of SUI in women, but tape-related complications have led to an increase in procedures to remove these devices. The uptake of botulinum toxin A and sacral neuromodulation has led to fewer clam ileocystoplasty procedures being performed. The steady increase in insertions of AUSs in men is unsurprising and reflects the widespread uptake of radical prostatectomy in recent years. There are limitations to results sourced from the HES database, with potential inaccuracy of coding; however, these data support the trends observed by experts in this field.
Collapse
Affiliation(s)
- John Withington
- Guy's and St Thomas' NHS Hospitals' Trust, King's College London, London, UK
| | | | | |
Collapse
|
23
|
Phé V, de Wachter S, Rouprêt M, Chartier-Kastler E. How to define a refractory idiopathic overactive bladder? Neurourol Urodyn 2013; 34:2-11. [DOI: 10.1002/nau.22512] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Accepted: 09/23/2013] [Indexed: 11/06/2022]
Affiliation(s)
- Véronique Phé
- Department of Urology, Pitié-Salpêtrière Academic Hospital; Assistance Publique-Hôpitaux de Paris, Pierre et Marie Curie Medical School, Paris 6 University; Paris France
| | - Stefan de Wachter
- Department of Urology; University Hospital Antwerpen; Antwerpen Belgium
| | - Morgan Rouprêt
- Department of Urology, Pitié-Salpêtrière Academic Hospital; Assistance Publique-Hôpitaux de Paris, Pierre et Marie Curie Medical School, Paris 6 University; Paris France
| | - Emmanuel Chartier-Kastler
- Department of Urology, Pitié-Salpêtrière Academic Hospital; Assistance Publique-Hôpitaux de Paris, Pierre et Marie Curie Medical School, Paris 6 University; Paris France
| |
Collapse
|
24
|
Repeated botulinum toxin type A (Dysport®) injections for women with intractable detrusor overactivity: a prospective outcome study. Int Urogynecol J 2013; 25:601-5. [DOI: 10.1007/s00192-013-2228-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2013] [Accepted: 09/01/2013] [Indexed: 11/30/2022]
|
25
|
Cui Y, Wang L, Liu L, Zeng F, Niu J, Qi L, Chen H. Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis. Urol Int 2013; 91:429-38. [PMID: 23970316 DOI: 10.1159/000351037] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2013] [Accepted: 04/01/2013] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To review the current evidence on the efficacy and safety of botulinum toxin-A in the management of idiopathic overactive bladder (OAB). METHODS A systematic search of PubMed, Embase and the Cochrane Central Search Library was performed. All randomized controlled trials comparing botulinum toxin-A with placebo, different doses and injection techniques, in patients with idiopathic OAB was included. The analyzed outcomes were quantification of symptoms, urodynamic outcomes, quality of life and adverse events. RESULT A total of 1,020 participants from 12 randomized controlled trials were included. Botulinum toxin-A was associated with less urinary frequency, less incontinence episodes, improvement in quality of life, higher post-void residual-related catheterization and higher urinary tract infection. Doses of 100-300 U were not consistently differentiated from each other in voiding diary, quality of life and urge urinary incontinence. No statistically significant difference was seen between bladder body and bladder base, bladder body and bladder body plus trigone in urinary retention and urinary tract infection. CONCLUSION Botulinum toxin-A is associated with significant improvement in OAB symptoms in patients with idiopathic OAB. However, there is a higher incidence of postoperative urinary retention and urinary infection compared to placebo. Low-dose botulinum toxin-A seems to be the optimum dose that appropriately balances the benefits with adverse events. Trigone inclusion seems as safe and effective as trigone-sparing injection.
Collapse
Affiliation(s)
- Yu Cui
- Department of Urology, Xiangya Hospital, Central South University, Changsha, China
| | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
Over the last 50 years, botulinum toxin has been transformed from a cause of life-threatening disease to an effective medical therapy. It has been used in a variety of specialties for different indications, significantly improving patient quality of life. A recent growing body of evidence suggests that intra-detrusor injection of botulinum toxin may have beneficial effects in patients with medication refractory detrusor overactivity and may offer a new minimally invasive alternative to patients with severe overactive bladder symptoms. To review current data regarding the effects of botulinum toxin in patients with overactive bladder, a MEDLINE®/PubMed® literature search was carried out. The mechanism of action, clinical usage, adverse effects, and treatment efficacy were reviewed and the results are presented in this paper.
Collapse
Affiliation(s)
- Bogdan Orasanu
- Departments of Urology and Obstetrics and Gynecology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH, USA
| | | |
Collapse
|
27
|
Okamura K, Takei M, Nojiri Y, Otsuka A, Takamoto H, Maeda Y, Fujimura T, Yokoyama T, Gotoh M, Homma Y. Twelve Months Follow-up of Injection of OnabotulinumtoxinA into Vesical Submucosa for Refractory Non-neurogenic Overactive Bladder. Low Urin Tract Symptoms 2013; 5:55-9. [PMID: 26663370 DOI: 10.1111/j.1757-5672.2012.00165.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE The aim of the present study was to assess the effects of onabotulinumtoxinA injection for refractory non-neurogenic overactive bladder (OAB) for 12 months. METHODS For patients with persistent urgency urinary incontinence (UUI) more than once a week despite taking anti-cholinergic agents or incapability to continue the agents because of adverse effects, 100 units of onabotulinumtoxinA was injected at 30 sites in the sub-epithelial bladder wall. Efficacy was assessed every month up to 12 months after injection, using a three-day frequency-volume chart (FVC) and postvoid residual urine (PVR), three questionnaires, and a simple score of Global Response Assessment (GRA). Failure was defined as when GRA was negative and additional treatment was administered. RESULTS Nine men and eight women aged 67 ± 12 years were included. On FVC, frequencies of urgency, UUI and daytime urination significantly decreased up to the 11th month. PVR significantly increased at the first and second months but no patient required catheterization. The total scores of Overactive Bladder Symptom Score and International Consultation on Incontinence Questionnaire Short Form were significantly decreased for 10 and eight months, respectively. The score of GRA was significantly improved for eight months. The median time to failure was 11.0 months. CONCLUSION This study suggests that onabotulinumtoxinA submucosal injection is promising for refractory non-neurogenic OAB. It is anticipated that the treatment is effective for eight to nine months and approximately 40% of the patients do not require anticholinergics at the 12th month postoperatively.
Collapse
Affiliation(s)
- Kikuo Okamura
- Division of Urology, Department of Surgery and Intensive Care, National Center for Geriatrics and Gerontology, Obu, JapanDepartment of Urology, Harasanshin Hospital, Fukuoka, JapanDepartment of Urology, Hamamatsu University, School of Medicine, Hamamatsu, JapanDepartment of Urology, Kurashiki Medical Center, Kurashiki, JapanDepartment of Urology, Aoyama Hospital Tokyo Women's Medical University, Tokyo, JapanDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanDepartment of Urology, Kawasaki Medical Hospital, Kurashiki, JapanDepartment of Urology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| | - Mineo Takei
- Division of Urology, Department of Surgery and Intensive Care, National Center for Geriatrics and Gerontology, Obu, JapanDepartment of Urology, Harasanshin Hospital, Fukuoka, JapanDepartment of Urology, Hamamatsu University, School of Medicine, Hamamatsu, JapanDepartment of Urology, Kurashiki Medical Center, Kurashiki, JapanDepartment of Urology, Aoyama Hospital Tokyo Women's Medical University, Tokyo, JapanDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanDepartment of Urology, Kawasaki Medical Hospital, Kurashiki, JapanDepartment of Urology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| | - Yoshikatsu Nojiri
- Division of Urology, Department of Surgery and Intensive Care, National Center for Geriatrics and Gerontology, Obu, JapanDepartment of Urology, Harasanshin Hospital, Fukuoka, JapanDepartment of Urology, Hamamatsu University, School of Medicine, Hamamatsu, JapanDepartment of Urology, Kurashiki Medical Center, Kurashiki, JapanDepartment of Urology, Aoyama Hospital Tokyo Women's Medical University, Tokyo, JapanDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanDepartment of Urology, Kawasaki Medical Hospital, Kurashiki, JapanDepartment of Urology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| | - Atsushi Otsuka
- Division of Urology, Department of Surgery and Intensive Care, National Center for Geriatrics and Gerontology, Obu, JapanDepartment of Urology, Harasanshin Hospital, Fukuoka, JapanDepartment of Urology, Hamamatsu University, School of Medicine, Hamamatsu, JapanDepartment of Urology, Kurashiki Medical Center, Kurashiki, JapanDepartment of Urology, Aoyama Hospital Tokyo Women's Medical University, Tokyo, JapanDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanDepartment of Urology, Kawasaki Medical Hospital, Kurashiki, JapanDepartment of Urology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| | - Hitoshi Takamoto
- Division of Urology, Department of Surgery and Intensive Care, National Center for Geriatrics and Gerontology, Obu, JapanDepartment of Urology, Harasanshin Hospital, Fukuoka, JapanDepartment of Urology, Hamamatsu University, School of Medicine, Hamamatsu, JapanDepartment of Urology, Kurashiki Medical Center, Kurashiki, JapanDepartment of Urology, Aoyama Hospital Tokyo Women's Medical University, Tokyo, JapanDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanDepartment of Urology, Kawasaki Medical Hospital, Kurashiki, JapanDepartment of Urology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| | - Yoshiko Maeda
- Division of Urology, Department of Surgery and Intensive Care, National Center for Geriatrics and Gerontology, Obu, JapanDepartment of Urology, Harasanshin Hospital, Fukuoka, JapanDepartment of Urology, Hamamatsu University, School of Medicine, Hamamatsu, JapanDepartment of Urology, Kurashiki Medical Center, Kurashiki, JapanDepartment of Urology, Aoyama Hospital Tokyo Women's Medical University, Tokyo, JapanDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanDepartment of Urology, Kawasaki Medical Hospital, Kurashiki, JapanDepartment of Urology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| | - Tetsuya Fujimura
- Division of Urology, Department of Surgery and Intensive Care, National Center for Geriatrics and Gerontology, Obu, JapanDepartment of Urology, Harasanshin Hospital, Fukuoka, JapanDepartment of Urology, Hamamatsu University, School of Medicine, Hamamatsu, JapanDepartment of Urology, Kurashiki Medical Center, Kurashiki, JapanDepartment of Urology, Aoyama Hospital Tokyo Women's Medical University, Tokyo, JapanDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanDepartment of Urology, Kawasaki Medical Hospital, Kurashiki, JapanDepartment of Urology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| | - Teruhiko Yokoyama
- Division of Urology, Department of Surgery and Intensive Care, National Center for Geriatrics and Gerontology, Obu, JapanDepartment of Urology, Harasanshin Hospital, Fukuoka, JapanDepartment of Urology, Hamamatsu University, School of Medicine, Hamamatsu, JapanDepartment of Urology, Kurashiki Medical Center, Kurashiki, JapanDepartment of Urology, Aoyama Hospital Tokyo Women's Medical University, Tokyo, JapanDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanDepartment of Urology, Kawasaki Medical Hospital, Kurashiki, JapanDepartment of Urology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| | - Momokazu Gotoh
- Division of Urology, Department of Surgery and Intensive Care, National Center for Geriatrics and Gerontology, Obu, JapanDepartment of Urology, Harasanshin Hospital, Fukuoka, JapanDepartment of Urology, Hamamatsu University, School of Medicine, Hamamatsu, JapanDepartment of Urology, Kurashiki Medical Center, Kurashiki, JapanDepartment of Urology, Aoyama Hospital Tokyo Women's Medical University, Tokyo, JapanDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanDepartment of Urology, Kawasaki Medical Hospital, Kurashiki, JapanDepartment of Urology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| | - Yukio Homma
- Division of Urology, Department of Surgery and Intensive Care, National Center for Geriatrics and Gerontology, Obu, JapanDepartment of Urology, Harasanshin Hospital, Fukuoka, JapanDepartment of Urology, Hamamatsu University, School of Medicine, Hamamatsu, JapanDepartment of Urology, Kurashiki Medical Center, Kurashiki, JapanDepartment of Urology, Aoyama Hospital Tokyo Women's Medical University, Tokyo, JapanDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanDepartment of Urology, Kawasaki Medical Hospital, Kurashiki, JapanDepartment of Urology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
28
|
Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system. J Neurol 2012; 260:701-13. [DOI: 10.1007/s00415-012-6615-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2012] [Revised: 07/06/2012] [Accepted: 07/09/2012] [Indexed: 11/26/2022]
|
29
|
Wöllner J, Schmidig K, Gregorini F, Kessler TM, Zbinden R, Mehnert U. Is there a direct antimicrobial effect of botulinum neurotoxin type A? BJU Int 2012; 110:E886-90. [PMID: 22882378 DOI: 10.1111/j.1464-410x.2012.11414.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
UNLABELLED Study Type--Therapy (case series) Level of Evidence 4. What's known on the subject? and What does the study add? Several studies describe a reduction of symptomatic urinary tract infections in patients with neurogenic detrusor overactivity after intradetrusor injections of botulinum neurotoxin A (BoNT/A). It was, however, unclear if a direct antibacterial effect of BoNT/A plays a role in this clinical observation. This is the first study to investigate a potential antibacterial effect of two frequently used BoNT/A formulations (i.e. Botox® and Dysport®), providing evidence that BoNT/A does not exert an antibacterial effect on lower urinary tract pathogens. OBJECTIVE • To determine a potential direct antimicrobial effect of botulinum neurotoxin type A (BoNT/A). MATERIALS AND METHODS • A prospective study was carried out using onabotulinumtoxin A (Botox®) and abobotulinumtoxin A (Dypsort®) in agar diffusion and broth microdilution assays with various clinical urinary tract isolates (Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Pseudomonas aeruginosa, Acinetobacter baumannii, Citrobacter freundii, Klebsiella oxytoca and Bacillus subtilis). • Inhibition zones (mm) of bacteria around a disc containing 20 µL saline with 4 IU of Botox® were measured in the agar diffusion assay. • Minimal inhibitory concentrations (MICs, IU/mL) of both toxins for all bacteria were determined in the broth microdilution assay after overnight incubation at 35 °C. RESULTS • There was no inhibition zone in the agar diffusion assays with any bacterial strain. • The microdilution test using Botox® and Dysport® showed bacterial growth in all dilutions, i.e. MICs > 20 and >100 IU/mL for Botox® and Dysport®, respectively. CONCLUSIONS • BoNT/A has no direct antimicrobial effect. • The reduced frequency of symptomatic urinary tract infections (sUTIs) in patients with neurogenic detrusor overactivity (NDO) after BoNT/A intradetrusor injections seems to be caused by different indirect mechanisms, which are still not completely understood.
Collapse
Affiliation(s)
- Jens Wöllner
- Neuro-Urology, Spinal Cord Injury Center & Research, University of Zurich, Balgrist University Hospital, Zurich, Switzerland
| | | | | | | | | | | |
Collapse
|
30
|
Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, Patel VD, Zhou J, Thompson C, Kowalski JW. OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial. Eur Urol 2012; 62:148-57. [DOI: 10.1016/j.eururo.2012.03.005] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2011] [Accepted: 03/05/2012] [Indexed: 10/28/2022]
|
31
|
Bauer RM, Gratzke C. Onabotulinumtoxin A for Idiopathic Overactive Bladder: Raising the Bar. Eur Urol 2012; 62:158-9. [DOI: 10.1016/j.eururo.2012.04.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2012] [Accepted: 04/10/2012] [Indexed: 10/28/2022]
|
32
|
Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2012; 111:106-13. [DOI: 10.1111/j.1464-410x.2012.11282.x] [Citation(s) in RCA: 90] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Amar Mohee
- Department of Urology; St James University Hospital; Leeds; UK
| | - Ayisha Khan
- Department of Urology; St James University Hospital; Leeds; UK
| | - Neil Harris
- Department of Urology; St James University Hospital; Leeds; UK
| | - Ian Eardley
- Department of Urology; St James University Hospital; Leeds; UK
| |
Collapse
|
33
|
Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection. Arch Gynecol Obstet 2012; 286:923-9. [DOI: 10.1007/s00404-012-2349-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2012] [Accepted: 04/17/2012] [Indexed: 10/28/2022]
|
34
|
Reply from Authors re: Christopher R. Chapple. Finding the Correct Starting Dose for OnabotulinumtoxinA. Eur Urol 2012;61:530–2. Eur Urol 2012. [DOI: 10.1016/j.eururo.2011.12.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
35
|
Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, Hermieu JF, Amarenco G, Karsenty G, Saussine C, Barbot F. Efficacy and Safety of Low Doses of OnabotulinumtoxinA for the Treatment of Refractory Idiopathic Overactive Bladder: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Dose-Ranging Study. Eur Urol 2012; 61:520-9. [DOI: 10.1016/j.eururo.2011.10.028] [Citation(s) in RCA: 130] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2011] [Accepted: 10/14/2011] [Indexed: 11/25/2022]
|
36
|
Allahdin S, Oo N. An overview of treatment of overactive bladder syndrome in women. J OBSTET GYNAECOL 2012; 32:217-21. [DOI: 10.3109/01443615.2011.649317] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
37
|
Chapple CR. Finding the correct starting dose for onabotulinumtoxinA. Eur Urol 2011; 61:530-2; discussion 532-3. [PMID: 22204746 DOI: 10.1016/j.eururo.2011.12.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2011] [Accepted: 12/05/2011] [Indexed: 10/14/2022]
|
38
|
Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011:CD005493. [PMID: 22161392 DOI: 10.1002/14651858.cd005493.pub3] [Citation(s) in RCA: 97] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND Overactive bladder syndrome (OAB) is a common condition with a significant negative impact on quality of life characterised by urgency with or without urge incontinence, frequency and nocturia. Intravesical botulinum toxin is being increasingly used to treat severe overactive bladder refractory to standard management. An increasing body of literature is forming that supports this technique as effective, well tolerated, and safe. This review is a substantial update of the 2007 review of the same title. OBJECTIVES The objective was to compare intravesical botulinum toxin with other treatments for neurogenic and idiopathic overactive bladder in adults. The hypothesis to be addressed were whether intravesical injection of botulinum toxin was better than placebo or no treatment; pharmacological and other non-pharmacological interventions; whether higher doses of botulinum toxin were better than lower doses; whether botulinum toxin in combination with other treatments was better than other treatments alone; whether one formulation of botulinum toxin is better than another; and whether one injection technique was better than another. SEARCH METHODS We searched the Cochrane Incontinence Group Specialised Trials Register (searched 23 February 2010). The Register contains trials identified from MEDLINE, CINAHL, the Cochrane Central Register of Controlled Trials (CENTRAL), and handsearching of journals and conference proceedings. Additionally, all reference lists of selected trials and relevant review papers were searched. No limitations were placed on the searches. SELECTION CRITERIA All randomised or quasi-randomised controlled trials of treatment for OAB in adults in which at least one management arm involved intravesical injection of botulinum toxin were included. Participants had either neurogenic OAB or idiopathic OAB with or without stress incontinence. Comparison interventions could include no intervention, placebo, lifestyle modification, bladder retraining, pharmacological treatments, surgery, bladder instillation techniques, neuromodulation, and different types, doses, and injection techniques of botulinum toxin. DATA COLLECTION AND ANALYSIS Binary outcomes were presented as relative risk and continuous outcomes by mean differences. Little data could be synthesised across studies due to differing study designs and outcome measures. Where applicable standard deviations were calculated from P values according to the formula described in section 7.7.3.3 of the Cochrane Handbook of Systematic Reviews of Interventions. Data were tabulated where possible with results taken from trial reports where this was not possible. Where multiple publications were found, the reports were treated as a single source of data. MAIN RESULTS Nineteen studies were identified that met the inclusion criteria. Most patients in the studies had neurogenic OAB, but some included patients with idiopathic OAB. All studies demonstrated superiority of botulinum toxin to placebo. Lower doses of botulinum toxin (100 to 150 U) appeared to have beneficial effects, but larger doses (300 U) may have been more effective and longer lasting, but with more side effects. Suburothelial injection had comparable efficacy to intradetrusor injection. The effect of botulinum toxin may last for a number of months and is dependent upon dose and type of toxin used. Patients receiving repeated doses do not seem to become refractory to botulinum toxin. Botulinum toxin appeared to have beneficial effects in OAB that quantitatively exceeded the effects of intravesical resiniferatoxin. Intravesical botulinum toxin appeared to be reasonably safe; however, one study was halted due to a perceived unacceptable rate of urinary retention. AUTHORS' CONCLUSIONS Intravesical botulinum toxin appears to be an effective therapy for refractory OAB symptoms, but as yet little controlled trial data exist on benefits and safety compared with other interventions, or with placebo. Further robust data are required on long term outcomes, safety, and optimal dose of botulinum toxin for OAB.
Collapse
Affiliation(s)
- James B Duthie
- Wellington Hospital, Riddiford Street, Newtown, Wellington, New Zealand, 6021
| | | | | | | | | |
Collapse
|
39
|
Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R, McDermott TED, Grainger R, Thornhill JA. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 2011; 61:928-35. [PMID: 22078337 DOI: 10.1016/j.eururo.2011.10.043] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2011] [Accepted: 10/27/2011] [Indexed: 11/25/2022]
Abstract
BACKGROUND Botulinum toxin A is effective for treatment of idiopathic detrusor overactivity (IDO). The trigone is generally spared because of the theoretical risk of vesicoureteric reflux (VUR), although studies assessing injection sites are lacking. OBJECTIVE Evaluate efficacy and safety of trigone-including versus trigone-sparing intradetrusor injections of abobotulinumtoxinA in patients with IDO. DESIGN, SETTING, AND PARTICIPANTS Twenty-two patients from one centre were randomised to trigone-including or trigone-sparing injections. INTERVENTION Injection of 500 U abobotulinumtoxinA diluted to 20ml into 20 trigone-including or trigone-sparing sites. MEASUREMENTS The primary outcome measure was total overactive bladder symptom score (OABSS) at 6 wk. The OABSS questionnaire was completed at 0, 6, 12, and 26 wk. Baseline and postinjection urodynamic studies and micturating cystourethrograms were performed. Baseline values and subsequent time points were compared by t test. A mixed-effect model was used for repeated measures in time. RESULTS AND LIMITATIONS For symptom scores at baseline compared with scores at 6 wk postinjection, the mean total OABSS improved from 22.4 to 8.7 (p<0.001) in the trigone-including group compared with 22.7 to 13.4 (p<0.03) in the trigone-sparing group. The difference in mean change from baseline was 4.4 points in favour of the trigone-including group (p=0.03). The total OABSS at 12 and 26 wk and the urgency subscale scores at 6, 12, and 26 wk showed significant improvement in favour of the trigone-including group. Mean postvoid residual volumes and clean intermittent self-catheterisation rates between the two groups were similar. No patients developed VUR. Performing injections under general anaesthetic was a limitation, as tolerability under local anaesthetic was not assessed. A further limitation is the lack of a trigone-only arm. CONCLUSIONS Trigone-including injections are superior to trigone-sparing injections for the treatment of refractory IDO and did not cause VUR in this study.
Collapse
|
40
|
Repeat Intradetrusor Injections of Onabotulinum Toxin A for Refractory Idiopathic Overactive Bladder Patients. Female Pelvic Med Reconstr Surg 2011; 17:253-7. [DOI: 10.1097/spv.0b013e31822f816f] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
41
|
Botulinum Toxin Type A in Patients With Parkinson's Disease and Refractory Overactive Bladder. J Urol 2011; 186:960-4. [DOI: 10.1016/j.juro.2011.04.071] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2011] [Indexed: 11/24/2022]
|
42
|
Abstract
Objectives: Sacral neuromodulation has gained increased worldwide acceptance as the standard of care in patients with refractory overactive bladder (OAB) and non-obstructive urinary retention (NOUR). This review will detail the evolution of the technology. Materials and Methods: The mechanism of action and advances in treatment, including tined lead, fluoroscopic imaging, and smaller implantable pulse generator (IPG) are reviewed. This discussion also explores expanding indications and future advances including interstitial cystitis, chronic pelvic pain, neurogenic bladder, fecal incontinence, constipation, and dysfunctional elimination syndrome in children. Results: Sacral neuromodulation (SNM) exerts its influence by modulation of sacral afferent inflow on storage and emptying reflexes. The tined lead allows for placement and stimulation to be performed in the outpatient setting under local anesthesia with mild sedation. Lead migration has been minimal and efficacy improved. The use of fluoroscopy has improved accuracy of lead placement and has led to renewed interest in bilateral percutaneous nerve evaluation (PNE). Bilateral PNE can be performed in the office setting under local anesthesia, making a trial of therapy less expensive and more attractive to patients. A smaller IPG has not only improved cosmesis, but decreased local discomfort and need for revision. The role for SNM continues to expand as clinical research identifies other applications for this therapy. Conclusions: Our understanding of SNM, as well as technological advances in therapy delivery, expands the pool of patients for which this form of therapy may prove beneficial. Less invasive instrumentation may even make this form of therapy appealing to patients without refractory symptoms.
Collapse
Affiliation(s)
- Jannah H Thompson
- Metropolitan Urology, Cornerstone Medical Specialty, 6025 Lake Road, Suite 100, Woodbury, MN, USA
| | | | | |
Collapse
|
43
|
Altaweel W, Mokhtar A, Rabah DM. Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder. Urol Ann 2011; 3:66-70. [PMID: 21747594 PMCID: PMC3130480 DOI: 10.4103/0974-7796.82170] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2010] [Accepted: 12/19/2010] [Indexed: 12/04/2022] Open
Abstract
Aim: To evaluate the clinical outcomes of two different doses of BTX-A in patients with refractory idiopathic overactive bladder. Patients and Methods: Thirty nine patients with refractory idiopathic overactive bladder from 1/1/2008 till 30/3/2009 were evaluated in a tertiary care hospital. Patients were evaluated using urodynamic studies, voiding diary, UDI-6 and IIQ-7 questionnaires prior to being prospectively randomized (alternate randomization) to the BTX-A applications and three months after treatment. Voiding diary and residual volume were followed two weeks later. All patients received intradetrusorial injections of BTX-A (Botox, Allergan, Irvine, CA) of 100u or 200u under cystoscopic control on an outpatient basis. The primary endpoint was assessed for the improvement of urodynamic parameters and adverse events at three months after the initial treatment. Secondary end points included urinary frequency, urgency and UUI episodes as assessed by voiding diary and QoL. Results: Eleven patients were enrolled to each arm of the study. There were no significant differences in demographic characteristics between the two groups. Urodynamic assessment at the end of the third month showed significant improvement in urodynamic variables in both groups. There was no statistically significant difference in urodynamic parameters and in the voiding diary between the two groups. QOL was significantly improved in both groups with no statistically significant difference between the different doses. Only three patients developed acute urinary retention. Conclusion: BTX-A at 100u and 200u appears to improve symptoms, urodynamic parameters and QoL with no statistical significance between the two groups.
Collapse
Affiliation(s)
- Waleed Altaweel
- King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia
| | | | | |
Collapse
|
44
|
Lahdes-Vasama TT, Anttila A, Wahl E, Taskinen S. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study. ACTA ACUST UNITED AC 2011; 45:397-400. [PMID: 21740110 DOI: 10.3109/00365599.2011.590997] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE This study aimed to investigate changes in urodynamic findings and symptoms after detrusor injections of botulinum toxin A (BTX-A) in children with idiopathic detrusor overactivity (IDO) and urge incontinence. MATERIAL AND METHODS Eight girls and five boys, aged 7-19 years, who had urge incontinence refractory to scheduled voiding and anticholinergics, were included this prospective study. Urodynamic studies showed postoperative IDO in 12 patients. A dose of 50-100 IU (1.3 -- 4.8 IU/kg) BTX-A was primarily administered at 15-20 detrusor sites. A control urodynamic study was performed within 3 months after the injections. Seven patients had a repeated procedure 16 (range 6-24) months on the average after the first one. RESULTS Eleven of the 13 patients had daily incontinence and two had incontinence a couple of times a week in association with urge symptoms. Postoperatively, no patient had urinary retention, but one girl had a urinary tract infection 4 months after the therapy. Five patients had a full response, seven partial responses and one no response 1-3 months after the first treatment. After 1 year, three of nine patients still have full response. Maximum cystometric capacity increased after the first treatment from a median of 227 ml to 379 ml (p = 0.005) and the number of patients with uninhibited detrusor contractions more than 30 cmH₂O during the filling phase decreased from eight to two out of 13 (p = 0.041). CONCLUSIONS Intradetrusor BTX-A injections effectively reduce day-time wetting, significantly increase bladder volume and decrease detrusor overactivity in children with urge incontinence refractory to scheduled voidings and anticholinergics.
Collapse
Affiliation(s)
- T T Lahdes-Vasama
- Department of Pediatric Surgery, Tampere University Hospital, Pediatric Research Centre, University of Tampere, Finland.
| | | | | | | |
Collapse
|
45
|
Steele SS. Botulinum toxin A: First-line therapy for idiopathic detrusor overactivity. Can Urol Assoc J 2011; 5:207-9. [PMID: 21672486 DOI: 10.5489/cuaj.11045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Stephen S Steele
- Assistant Professor, Departments of Urology and Pediatrics, Queen's University, Kingston, ON
| |
Collapse
|
46
|
Gamé X, Khan S, Panicker JN, Kalsi V, Dalton C, Elneil S, Hamid R, Dasgupta P, Fowler CJ. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. BJU Int 2010; 107:1786-92. [PMID: 21040367 DOI: 10.1111/j.1464-410x.2010.09791.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
STUDY TYPE Therapy (case series). LEVEL OF EVIDENCE 4. What's known on the subject? and What does the study add? We know that repeated injections of botulinum toxin A are effective in treating refractory detrusor overactivity particularly in NDO. This study shows that in both NDO and IDO repeated injections of the toxin improve quality of life as assessed by three validated questionnaires. The effect is most marked after the first injection in NDO patients but thereafter similar in both groups. OBJECTIVE To compare the effect of repeated detrusor injections of botulinum toxin (BoNT-A) on health-related quality of life (HRQL) in patients with idiopathic (IDO) or neurogenic detrusor overactivity (NDO). PATIENTS AND METHODS Between 2003 and 2009, 151 patients (109 with NDO and 42 with IDO) were treated by BoNT-A (Botox®, Allergan Inc., Irvine, CA, USA). Changes in HRQL were assessed using the validated short forms of Urogenital Distress Inventory (UDI-6), the Incontinence Impact Questionnaire (IIQ-7) and EuroQOL-5D (EQ-5D) before and 4 weeks after BoNT-A. RESULTS The maximum number of repeated injections was five (mean±sd, 2.8±1.05). Mean±sd follow-up was 27.49±17.01 months. The UDI-6 and IIQ-7 questionnaires showed a consistent improvement after repeated injections in both groups with detrusor overactivity. The EQ-5D was not statistically different before and after each injection in either the NDO or IDO population. After repeated injections, no statistical differences in the change on the UDI-6 and IIQ-7 scores were found between NDO and IDO, except after the first treatment, when the decrease in UDI-6 was higher in NDO than in IDO. The EQ-5D anxiety and depression subscore improved in both groups after each injection and with the number of injections. In IDO, after the second injection, no patient reported extreme anxiety or depression and, after the fourth injection, none had anxiety or depression. The inter-injection interval was shorter after the first injection in those with NDO than in IDO but was similar thereafter. CONCLUSIONS Intradetrusor injections of BoNT-A improved the HRQL of both NDO and IDO patients. Although improvement in HRQL was greater and the duration of efficacy shorter in NDO patients after the first injection, there was no significant difference after subsequent injections. Mean inter-injection interval in IDO and in NDO patients was similar from the second injection onwards and improvements in HRQL score were the same.
Collapse
Affiliation(s)
- Xavier Gamé
- Department of Uro-Neurology, UCL Institute of Neurology, The National Hospital for Neurology and Neurosurgery, and Medical Research Council (MRC) Centre for Transplantation, King's College London, London, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
|
48
|
|
49
|
Shaban A, Drake MJ, Hashim H. The medical management of urinary incontinence. Auton Neurosci 2009; 152:4-10. [PMID: 19900845 DOI: 10.1016/j.autneu.2009.09.022] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2009] [Revised: 09/25/2009] [Accepted: 09/28/2009] [Indexed: 11/30/2022]
Abstract
Urinary incontinence is the involuntary leakage of urine; it affects millions of people worldwide, causing significant detrimental effects on their quality of life. Direct expenses, such as containment products, long-term drug prescriptions and surgery, complemented by indirect costs, such as reduced employment productivity, result in overall expenditure running to billions of dollars. Stress urinary incontinence (SUI) occurs on physical exertion, and results from weakness of the bladder outlet. Urgency urinary incontinence (UUI) results from inability to resist a sudden compelling desire to pass urine, arising as a consequence of bladder dysfunction. Clinical evaluation clarifies the underlying mechanisms and excludes diseases causing similar symptoms. Urodynamic studies to measure bladder and abdominal pressures and deduce the bladder and outlet function are undertaken when invasive treatments are being considered or when the nature of the incontinence is not entirely clear. Initial management of SUI involves pelvic floor muscle exercise training; if insufficient symptom improvement results, surgical measures are needed. UUI treatment commences with advice on suitable fluid intake and measures to improve ability to defer voiding, followed by antimuscarinic drugs. Refractory UUI is a difficult problem, currently managed with a range of surgical interventions, including bladder injections of botulinum-A neurotoxin, augmentation cystoplasty and nerve stimulation methods. New treatment options are needed, because of the risk of impeding voiding function, resulting in urinary retention. Persistent leakage is controlled with containment products, such as pads, or collection devices, such as catheters.
Collapse
Affiliation(s)
- Ahmed Shaban
- Bristol Urological Institute, Southmead Hospital, Bristol, BS10 5NB, UK
| | | | | |
Collapse
|